0001104659-08-024236.txt : 20080414 0001104659-08-024236.hdr.sgml : 20080414 20080414171019 ACCESSION NUMBER: 0001104659-08-024236 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080414 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20080414 DATE AS OF CHANGE: 20080414 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARQULE INC CENTRAL INDEX KEY: 0001019695 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043221586 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21429 FILM NUMBER: 08755188 BUSINESS ADDRESS: STREET 1: 19 PRESIDENTIAL WAY CITY: WOBURN STATE: MA ZIP: 01801 BUSINESS PHONE: 781-994-0300 MAIL ADDRESS: STREET 1: 19 PRESIDENTIAL WAY CITY: WOBURN STATE: MA ZIP: 01801 8-K 1 a08-10808_18k.htm 8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2008

ARQULE, INC.

(Exact Name of Issuer as Specified in Charter)

Delaware	000-21429	04-3221586
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification No.)

19 Presidential Way

Woburn, MA

(Address of principal executive offices)

01801

(Zip code)

(781) 994-0300

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 8 — Other Events

Item 8.01 Other Events.

On April 14, 2008, ArQule, Inc. (the “Company”) issued a press release announcing that its Annual Meeting of Stockholders (the “Annual Meeting”) will be held on May 15, 2008, instead of May 16, 2008. The date of the Annual Meeting has been changed to correspond to the Board of Directors meeting scheduled on that day in order to give the directors the opportunity to attend the Annual Meeting. Additional information regarding the time and location of the Annual Meeting, the record date and the agenda is included in the Company’s proxy statement that today was filed with the Securities and Exchange Commission and mailed to stockholders.

The press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.

Section 9 — Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press release of ArQule, Inc., dated April 14, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ARQULE, INC.
	(Registrant)


		/s/ Peter S. Lawrence
		Peter S. Lawrence
		President and Chief Operating Officer

April 14, 2008

EX-99.1 2 a08-10808_1ex99d1.htm EX-99.1

Exhibit 99.1

	Contact:
	William B. Boni
	VP, Investor Relations/ Corp. Communications
	(781) 994-0300
	www.ArQule.com

FOR IMMEDIATE RELEASE:

ARQULE ANNOUNCES DATE CHANGE OF 2008 ANNUAL MEETING OF
STOCKHOLDERS TO MAY 15, 2008

Woburn, MA, April 14, 2008 — ArQule, Inc. (NASDAQ: ARQL) today announced that its 2008 annual meeting of stockholders will be held on May 15, 2008, instead of May 16, 2008, as previously announced in the company’s annual report on form 10-K.

The annual meeting date has been changed to correspond to the board of directors meeting scheduled on May 15, 2008 in order to give the directors the opportunity to attend the annual meeting.

Additional information regarding the time and location of the annual meeting, the record date and the agenda is included in the Company’s proxy statement that was filed today with the Securities and Exchange Commission and mailed to stockholders.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s clinical-stage products consist of ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase, and ARQ 501, an activator of the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s most advanced pre-clinical development programs are focused on ARQ 761, a second-generation E2F-1 activator, as well as compounds that inhibit the Eg5 kinesin spindle protein and the B-RAF kinase. ArQule’s discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells. For more information, please visit www.arqule.com.

# #